WHO says 2 Ebola vaccine candidates to enter phase 2 trials next week in DRC

What the report says
The World Health Organization said two Ebola vaccine candidates are set to move into phase 2 trials in the Democratic Republic of the Congo next week, according to Anadolu Agency Africa. The candidates are linked to Oxford University and the Serum Institute of India, as well as Moderna, and the move is part of a broader effort to strengthen protection against Ebola in the country.
The report says more than 140 participants have already been enrolled in the wider trial program. That step suggests the study is progressing beyond initial testing and into a stage focused on further evaluating safety and immune response in a real-world outbreak setting.
The development matters because the DRC has faced repeated Ebola outbreaks, making vaccine research and deployment an important public health priority. While the article text provided does not include detailed trial locations, timelines beyond next week, or results from earlier phases, the WHO’s announcement indicates continued international coordination on Ebola countermeasures.
In general, phase 2 trials are designed to build on earlier safety findings and gather more data on how well a candidate may work. The report underscores ongoing efforts to advance multiple vaccine options at once, which can help public health agencies respond more quickly if another outbreak worsens.
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.

Miami court convicts US-Haitian pastor over 2021 assassination of presidentAl Jazeera
How to Decode the Xi-Trump HugNew York Times World
APEC Live: Trump, Xi and Putin to meet in historic three-way China summitAl Jazeera
Was China Sending a Musical Message to Japan’s Takaichi During APEC Welcome?New York Times World
China’s Xi greets Putin and Trump at APEC before historic summitAl Jazeera